MPN Watch

Dossier pubmed case report 04-oct-2026

Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.

Key claim: Momelotinib induced hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.

Abstract

No abstract available.

Why this matters

Classical momelotinib evidence comes from JAK2V617F- and CALR-driven myelofibrosis, leaving an open question whether anemia/symptom benefits generalize to rarer JAK2-rearranged entities. This case report extends the drug’s clinical profile to PCM1::JAK2 fusion disease, suggesting the mechanistic rationale (JAK2 pathway activation) translates across quite different genotypic contexts and giving clinicians a documented option for a subtype with very few evidence-based therapies.

Source

Link

Briefing card

Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.
Stage: case report · pubmed · 04-oct-2026

If you have a PCM1::JAK2 fusion-driven myeloid neoplasm with anemia and symptoms, this case report suggests momelotinib can improve both.

Momelotinib induced hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

🔎 Pulled in by auto-added search #66 (pubmed): ("ACVR1"[Title/Abstract] OR "ALK2"[Title/Abstract] OR hepcidin[Title/Abstract] OR ferroportin[Title/Abstract] OR momelotinib[Title/Abstract] OR rusfertide[Title/Abstract] OR BMP6[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR myeloproliferative[Title/Abstract])

External: doi:10.1016/j.leukres.2026.108337

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11